Area of research
Genetics · Hematology
Research interest
Research interests include Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Acute Myeloid Leukemia Research, and Eosinophilic Disorders and Syndromes.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement and pemigatinib.
Response to the commentary by Xu et al. on the PV-AIM study.
Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Scalable genotyping in fixed transcriptomes resolves clonal heterogeneity via single-cell sequencing
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Pemigatinib for Myeloid/Lymphoid Neoplasms with <i>FGFR1</i> Rearrangement
Current myeloproliferative neoplasm scoring systems for clinical practice.
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis
A molecular signature predicts hematologic evolution in polycythemia vera patients.
Synergistic effect of concurrent high molecular risk mutations and lower JAK2 mutant variant allele frequencies on prognosis in patients with myelofibrosis-insights from a multicenter study.
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.
Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination
Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC-PM.
Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis
Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Biological drivers of clinical phenotype in myelofibrosis.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Comprehensive response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: a proposal from the MLN International Working Group
Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies.
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.